arrow
A

Anna Vulpetti

novartis institutes for biomedical research
H指数:36
被引数:5,089

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fragment-based discovery enables direct targeting of the melanoma oncogene MITF

片段筛选方法能够直接靶向黑色素瘤癌基因MITF

2025-12-090
OAAI
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance (vol 15, 275, 2024)
2024-08-190
OAAI
Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches
2024-05-100
PRE
Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates
2024-01-243
PRE
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
2024-01-0421
OA
Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase
2023-11-1315
PRE
Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field

发现DCAF1的新结合物,DCAF1是靶向蛋白质降解领域中的新兴连接酶靶标

2023-06-0218
PRE
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway
2019-04-1715
PREAI
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo
2017-06-3028
PREAI